Childhood cancer is a major global health issue. Every year, almost 100 000 children die from cancer before the age of 15 years, more than 90% of them in resource-limited countries. Here, we review the key policy issues for the delivery of better care, research, and education of professionals and patients. We present a key list of time-limited proposals focusing on change to health systems and research and development. These include sector and system reforms to make care aff ordable to all, policies to promote growth of civil society around both cancer and Millennium Development Goals, major improvements to public health services (particularly the introduction of national cancer plans), improved career development, and increased remuneration of specialist health-care workers and government support for childhood cancer registries. Research and development proposals focus on sustainable funding, the establishment of more research networks, and clinical research specifi cally targeted at the needs of low-income and middle-income countries. Finally, we present proposals to address the need for clinical trial innovation, the complex dichotomy of regulations, and the threats to the availability of data for childhood cancers.
Introduction
In 1980, the World Development Report 1 emphasised that developing countries are home to 78% of the global population, but to 86% of the world's children. The proportion of children in developing countries is expected to increase to more than 90% by 2030. Although infectious diseases are much more prevalent than cancer in developing countries, more deaths are caused by cancer worldwide than by HIV infection, tuberculosis, and malaria combined; cancer incidence is higher in developing countries (147 000 cases per year) than in developed countries, and is growing because the populations in these countries are younger and expanding. 2 As a result, up to 2% of all cancers in developing countries arise in children, whereas in Europe and North America, childhood cancers constitute less than 0·5% of total incident cases. The essential policy issues framing the global care agenda for children with cancer are not only those intrinsic to paediatric oncology, but-particularly in developing countries-are also a product of a country's stage of economic development, its ensuing patterns of disease, and the sociopolitical constructs that aff ect health (fi gure 1). 3 According to estimates by the International Agency for Research on Cancer for 2008, almost 100 000 deaths before the age of 15 result from cancer every year, and more than 90% of these deaths occur in low-middle income countries (fi gure 2). 2 With continued socioeconomic development, the proportion of deaths from cancer is likely to increase in developing countries, especially in young people. Mortality is high in developing countries-80% of young cancer patients in Africa die, including in countries with more developed health systems such as South Africa. Available data probably underestimate the burden of childhood cancer in developing countries because the patterns of occurrence suggest that many patients die from undiagnosed cancer.
Nowadays, about 80% of children with cancer in highincome countries survive. 4 However, in resource-limited settings, many cases of cancer are detected too late for eff ective treatment, and are compounded by comorbidities (especially malnutrition), aff ordability, and restricted access to treatment and care. 5 The burden and range of childhood cancers varies substantially between countries. Global policies to address the care, education, and study of children with cancer and their families need to deal with both commonalities-eg, the eff ect of legislation on childhood cancer research and development-and the specifi c contexts of where these children live. Because socioeconomic, demographic, and Series political circumstances vary widely in developing countries, eff ective cancer treatment for children will need strategies that are adapted to individual countries with limited resources. The policy myth that developing countries cannot aff ord to treat children with cancer needs to be debunked. High cure rates in children result in many potential years of life saved, and for some childhood cancers, such as Burkitt's lymphoma and Wilms' tumour, aff ordable treatments can be highly eff ective when given appropriately. 6 Formal economic evaluation, by use of quality-adjusted life-years, has shown that treatment of cancer in children is a very costeff ective investment, 7, 8 particularly for cancers such as Burkitt's lymphoma and acute lymphoblastic leukaemia, which are curable in children.
The quantity and quality of statistics describing burden of disease in developing regions vary. In Africa, only three countries-Mauritius, South Africa, and Egyptprovide cancer mortality statistics to the WHO mortality database, and only about 1% of the African population is covered by reliable population-based cancer registries providing data on cancer incidence (fi gure 3). 9 The population data-which are needed to produce incidence and mortality rates-are not available or are insuffi cient; therefore, the statistics are based on little real data. Existing population-based cancer registries are the forerunners of the cancer control plan, and should therefore receive wide-ranging support to continue providing unique and indispensable information about cancer burden. 10 Despite resource limitations, several middle-income countries-eg, Argentina, South Africa, and Iran-have implemented national population-based cancer registration for children, with support from nongovernmental organisations in some cases.
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In high-income countries in the past few decades, the most substantial gains in outcomes have been in childhood cancers. 5-year survival has increased from less than 30% in the 1960s to about 80% in the 2000s for all childhood cancers combined. 12, 13 The most important reason for this achievement is the integration of care and research in paediatric oncology; however, serious policy issues exist-eg, the future sustainability of research and development, integrated care networks, and the eff ect of regulations. We look at the issues and solutions from the other papers in this Series [14] [15] [16] and propose solutions for all children with cancer for the next decade, irrespective of where in the world they live.
High-income countries: changing the policy landscape
Outcomes in children in high-income countries have substantially improved, but have varied with cancer type and geography.
14 Despite an overall improvement in childhood 5-year survival, 12, 13 several solid cancers are still refractory to treatment. As discussed by Vassal and colleagues, 16 this lack of response is partly attributable to a lag in the scientifi c understanding of these types of cancer, but also to the translation of adult research and development into the paediatric setting. Importantly for policy makers at the national and supranational level, Pritchard-Jones and colleagues 14 state that improvements in effi cacy of present regimens and treatment approaches are reaching their limit, and, despite substantial improvements in outcomes, we are a long way from curing all children with cancer. Furthermore, even for the children saved by present approaches, long-term toxicity and the associated eff ects on future health remain important. 17 The risks include continuing excess mortality, second primary neoplasms, neurocognitive defects, cardiovascular disease, other organ dysfunction, and the psychosocial eff ects of disease and its treatment on the patient and their family. 18 The policy environment for adults who survived childhood cancer needs to be reviewed, irrespective of any health consequences. Survivors aged 30-50 years have much the same general indicators of economic achievement and insurability as do people in the same age group who did not have cancer as children. 19 But despite this, survivors in this age group are denied entry into the military and can have applications for life insurance rejected. Survivors aged 20-29 years are worse off than those who have not had cancer in several areas including educational achievement, employment, workplace and social relationships, and the ability to obtain health and life insurance.
Although we have the knowledge and methods to deliver excellent outcomes in many childhood cancers, the diff erences in outcomes between more and less affl uent populations-irrespective of whether these are in highincome or low-income countries-is concerning. In developing countries, one of the strongest determinants of childhood mortality is the socioeconomic class of parents (fi gure 4). 20 In high-income settings, diff erences in geographical outcome fell between 2005 and 2009; however, childhood cancer mortality is more than 20% higher in central and eastern Europe than in the rest of Europe (fi gure 5). 20 To close this gap, the underlying reasons for the divergence need to be understood, and social and health policies need to be introduced. Attempts to help with transnational clinical research in Europe have unintentionally had negative consequences. 22 Paediatric oncology groups from several central and eastern European counties were involved in international clinical trials before their countries joined the European Union (EU); almost all of the front-line treatments involved the off -label use of long established medicines that were out of patent. This situation was generally accepted by regulatory authorities, and the trials were seen as obligatory standards for the treatment of childhood cancer. However, implementation of European directives led to the overinterpretation of some regulatory requirements, without any funding to support the infrastructure changes necessary for compliance. Both research-active care networks and the viability of the care centres were adversely aff ected. For example, Polish paediatric oncology centres are not currently able to open any new academic clinical trials because the universities do not have the resources to meet the responsibilities assigned to the sponsor role by the Polish Government. 23 Very little government or philanthropic funding is available to support cancer care in these countries. 24 From a policy perspective, the crucial work is to attempt to revise European clinical trials legislation and provide advocacy, such as the European Society of Paediatric Oncology's promotion of national support for childhood cancer research.
Although comparable statistics are available in highincome countries, funding cuts and unjustifi ed requirements on data confi dentiality pose a challenge to established cancer registries. National population-based cancer registries should be advocated for childhood cancers because of their rare occurrence, centralised treatment, internal migration, data quality, and cost considerations, as recommended by EUROCOURSE ERA-Net. To improve interpretation of follow-up and outcome data, clinical trial groups or consortia can enhance the quality of their data and enlarge their database with clinically relevant information. Additionally, precise statistics can help to identify gaps and outline directions for improvement-further reduction of mortality, extension of long-term survival, and limitation of treatment-related late side-eff ects. 25 Registries are not just important in high-income countries, and policy makers can learn from good models being implemented in emerging economies such as South Africa. 26 Why have the cancer communities in high-income countries been so successful in improving outcomes in the past 30 years? One of the major lessons learnt has been for the care and research communities to organise themselves to deliver a continuously innovating system of care, with research fully integrated into clinical pathways. Innovation in the organisation of care in high-income countries has enabled the localisation and eff ective networking of appropriate expertise, data collection, and research. Clinical trials have also had an important role in the improvement of outcomes; the accrual rate is an order of magnitude greater for children than for adults in highincome countries, and enrolment on available clinical trials at fi rst diagnosis has become the standard of carean important point often not acknowledged by policy makers. The eff ective management of children with cancer needs long-term commitment from both healthcare professionals and federal authorities to support research and care networks. The gains in outcomes should be seen in the context of other major issues, and drawbacks that arise as health-care and political systems change. In terms of policy, high-income countries still need continuous vigilance and development.
Low-income countries: improving outcomes
The burden and eff ect of childhood cancers in developing countries is complex; level of income, social indicators (eg, general health and education), vulnerability and risk, and sociopolitical access all play a part. 27 Poverty aff ects health and mortality at all ages, but particularly children, including those children from less affl uent backgrounds in high-income countries. 28 As well as the direct eff ect of poverty, low-income countries have poor health-care provision, which means that few special cancer centres Series are available, and if they are, they are likely to be a long and expensive journey away. 80% of people in Africa have no access to radiotherapy, cancer surgery, or the infrastructure needed for the basic delivery of cancer care. 29 Suffi cient numbers of health-care workers and adequate levels of fi nancial capital to bring health care to all do not exist. Such substantial intrinsic hurdles seriously compromise the development of services for children with cancer. From a policy perspective, catalytic programmes are needed to overcome this inertia. 30 Twinning is extremely important; the term encompasses the engagement of centres in high-income countries with developing countries, but also more regional programmes such as the links between Northern and South Africa with sub-Saharan Africa. 31 Developing countries can be optimistic for the future. Social and health conditions are improving in many parts of the world-eg, growth in per-person private consumption in developing countries increased from 1·4% per year between 1980 and 1990, to 2·4% between 1990 and 1999, and the percentage of people living in extreme poverty (ie, less than US$1 a day) fell from 28% in 1987 to 23% in 1998, and 19% in 2009. Policies to increase social capital-ie, the development of social relations and networks that produce strong societal bonding, mutuality, and solidarity-around children with cancer will play a major part in the delivery of better access and services. 32 While patients' organisations and advocacy movements are a young social phenomenon in many developing countries, the drive to create them has been led by the childhood cancer community in many parts of the world. Wilkinson 33 stated that social capital is essential for the enhancement of equitable service performance through the engagement of civil society to advocate for services and hold providers to account. The eff ect of poor social capital on outcomes in children with cancer is pronounced. In one study of outcomes in children with acute lymphoblastic leukaemia in Indonesia, 47% of parents from deprived areas refused or abandoned treatment compared with 2% from affl uent areas. 34 The same study suggested that strong social hierarchical structures hindered communication with doctors, and resulted in insuffi cient parental understanding of the need to continue treatment.
Infant mortality rates fell from 107 to 59 per 1000 livebirths between 1970 and 1999, and adult literacy rose from 53% in 1970 to 74% in 1998. 35 These changes are important because a lack of young people who are Series qualifi ed to attend university limits the capacity for training health-care workers. Cancer care depends on a range of professions, including engineers, pharmacologists, and many specialists such as ophthalmologists, radiologists, and pathologists, in addition to the oncology community. The introduction of education and social capital policies in developing countries, and the development of dedicated units for treating children with cancer, will be essential for the delivery of adequate childhood cancer services. 36 The most important determinant of outcome for a child with cancer is where he or she is born. In south Asia, four out of ten households (more than 500 million people) are in poverty, and infant and child mortality varies widely between diff erent regions. In our health lifecycle, childhood is one of the most vulnerable periods with respect to disease and ill health because of biological and socioeconomic immaturity; therefore, children suff er the consequences of poverty more than adults. 37 Parental income is an important determinant of child cancer inequalities across countries, but other determinantseg, education, the political situation, and environ mentare also important. 38 Average country income has a strong indirect eff ect on maternal education, which has a major infl uence on child health. 39 Maternal education is closely related to a woman's control over household issues, including awareness of health issues. Additionally, accessibility to health services is very important; countries that have achieved good health at low cost also had health systems that were free at the point of delivery and easy to access. Unsurprisingly, high maternal mortality rates are associated with regions of high childhood cancer mortality. Diff erences between regions in female access to education also aff ect the ability of countries to deliver improved childhood cancer services-eg, India has a 16·6% diff erence between the school enrolment of girls and boys aged 6-14 years. In Niger, the enrolment rate of boys is 41% higher than that of girls. The development of health policy is as important as are cancer-specifi c initiatives in developing countries.
New policies to support research into childhood cancer A new paradigm for drug development
Drug development for cancer has progressed from cytotoxic regimens to molecularly targeted agents. 40 Molecular dissection, targeted agents, and biomarker codevelopment have shaped and driven adult oncology, and are now being applied to some childhood cancers previously defi ned in anatomical terms-eg biomarkers are available for medulloblastoma and neuroblastoma. 41 However, increased understanding of the complex biology of certain cancers, and their subsequent molecular characterisation, has not been easily or quickly translated into improved outcomes. This shortfall might be an issue of scientifi c progress in the elucidation of complex biological pathways in childhood cancers, or something more fundamental-eg, higher-resolution pictures of cancer might not necessarily translate into improved outcomes. Likewise, Vassal and colleagues 16 point out that only some of the identifi ed targets might be treatable with present technologies. Furthermore, the economic ability to develop drugs for rare targets is a serious policy issue. Although molecular characterisation of adult malignant disease has paved the way for novel drug development, many of the paediatric targets diff er Series from those in adults. Big challenges remain in the translation of the science of childhood cancers into new drugs, and specifi c programmes and funds are needed to drive this fundamental research. 42 Moreover, the shortterm and long-term toxicity profi les of these new agents are very unpredictable.
Importance of clinical trials
Clinical trials have had, and will continue to have, an essential role in the development of novel drugs for children with cancer. The high rates of recruitment to clinical trials contributed to one of paediatric oncology's greatest achievements-a substanital improvement in survival. However, as the biology of childhood cancers becomes better understood, 43 and more targeted drugs are developed, the paediatric research community needs to embrace novel trial designs and biomarker codevelopment strategies. 44 Other crucial areas for evolution are the harmonisation of response defi nitions, and the use of response as a continuous variable. Importantly, for development of cooperative clinical trials between North America and Europe, harmonisation of procedures and biomarker development is urgently needed. 45 Furthermore, the codevelopment of biomarkers found from biospecimen collection and the addition of various novel imaging methods in several trial settings need to catch up with the adult fi eld. Beyond the issue of trial design development, the division between clinical trial outcomes, overall service outcomes, and service improvement processes is a problem. Paediatric oncology research progressed quickly during the 1980s and 1990s because the boundary between research and service improvement was less obvious than it is now. As clinical trials develop and become more focused because of the molecular characterisation of cancers, inclusion criteria will become more rigorous and, therefore, will exclude many patients. To ensure outcome is not compromised, patients who do not enter trials should undergo the same rigor of investigation and staging of disease as do patients in clinical trials. Countries should ensure that quality outcomes are monitored both nationally and for each treating centre.
Treatment of children with cancer in the foreseeable future will continue to rely on regimens using chemotherapy and radiotherapy, 46 both of which have serious immediate and long-term issues of toxicity. 47 Academic programmes and trial investigators need to better prospectively explore cohorts of survivors, and to propose adapted care for adults with long-term eff ects of their childhood cancer treatment. This approach will include more research into mitigation of the eff ects of toxicity from present regimens and novel targeted agents 48 and guaranteed long-term follow-up of survivors. This latter point is particularly important as current pharmacovigilance requirements provide little mandated follow-up data for new medicines.
Collaboration and funding
In view of the increased biological, organisational, and regulatory complexity, and the diversity of research and development in childhood cancers, what new models are needed? Vassal and colleagues remind us that "Time is an issue. Speed up new drug development for our children". 16 Therefore, new models of partnership and collaboration are as much about delivering new solutions quickly as they are about innovation. In highincome countries, the paediatric research and development community have long had well organised collaborations between patients, parents, clinicians, and scientists. 49 However, the interface with the adult drug development community and the pharmaceutical industry still has major gaps.
The continuation and advancement of research into children with cancer depends on long-term, sustainable funding; however, evidence suggests that paediatric research and development is reliant on short-term, unsustainable funding (fi gure 6). Despite new initiatives, this short-termism is a major concern. The US National Cancer Institute and other parts of the National Institutes of Health have dominant roles in North America, and fund almost half of all paediatric oncology research in the USA. 50 In Sweden, charities and endowed foundations fund more than 40% of research. Other nationally prominent European funders include the Associazione Italiana per la Ricerca sul Cancro in Italy, Deutche Krebshilfe in Germany, the Netherlands Cancer Society, and Cancer Research UK. The European Commission funds only 7% of childhood cancer research. The support of paediatric oncology research by the EU is a positive step, but it is inadequate for the scale of the problem. Furthermore, at the national level, funding is too low or too unstable, with much activity reliant on short-term funding. National and international funding needs to be more sustainable and coherent.
The role of the pharmaceutical industry
What is the best way to identify eff ective treatments for childhood cancers? In view of the complex and heterogeneous nature of these cancers, the trend in the past few years for industry to drive the development of clinical research plans contrasts with the need for broad research and development partnerships that can deal with complex biology and drug development. Companies are developing research plans to meet regulatory obligations related to the drugs that they are developing for adult cancers. This trend takes the primary responsibility for research direction away from the larger paediatric oncology community, and also tends towards the fragmentation of childhood cancer clinical research activities-as opposed to the cooperative, unifi ed clinical research activities that are needed in view of the small numbers of children with specifi c cancer types. Thus, the long-term eff ects of this trend raise serious concerns.
Series Regulation
Re gulation aff ecting research and development in childhood cancers has had both adverse and benefi cial consequences. For example, in Europe, the Clinical Trials Directive has had devastating eff ects on several publicly funded clinical trials, particularly those focused on childhood cancers. However, these international clinical trials have delivered, and will continue to, deliver excellence in care and new treatment strategies. 51 The Clinical Trials Directive has almost quadrupled costs and led to substantial delays and even the discontinuation of trials. 52 Additionally, data protection legislation (the 1995 Data Protection Directive in Europe and the Health Insurance Portability and Accountability Act in North America) has negatively aff ected the ability of the paediatric research community to share data internationally, and hindered the activity of essential registries. In Europe at least, policy makers seem to fi nd it diffi cult to create legislation that promotes, rather than inhibits, life-saving research. A planned revision to the European Data Protection Directive is causing major concerns among cancer registries and researchers that this work will be discontinued. 53 Another regulation issue was the attempt to improve pipelines of novel compounds by regulatory mechanisms to drive crossover of adult new molecular entities to the paediatric setting. In 1997, the USA, and in 2007, the EU, introduced regulations for improved drugs for children with cancer. In the USA, two pieces of legislation, the Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act cover the need for paediatric information for approved drugs. These regulations have substantially aff ected drug development for children with cancer, and other childhood diseases. 54 All pharmaceutical companies must now consider paediatric oncology in their development programmes. However, too many companies view childhood oncology as a regulatory requirement to comply with, rather than having a biology-based research and development approach that integrates into the paediatric setting. 55 Furthermore, plans for drugs to meet regulatory requirements in children are inherently drug-focused rather than disease-focused; as a result, the clinical trials proposed for a particular drug might be of low clinical relevance or the eligible paediatric patients might be extremely rare. Clinical cancer research should maintain disease-focused prioritisation of clinical research led by the paediatric oncology expert community rather than drug-focused prioritisation led by pharmaceutical companies and regulatory authorities.
In low-income and middle-income countries, several types of research are needed for progress. Because local conditions change as new infrastructure and personnel become available, the adaptation of treatment regimens to local conditions is a continuous project. Therefore, a system of continuous quality improvement should become habitual in developing countries, so that clinicians can cure as many children as possible with existing resources, while simultaneously improving knowledge and infrastructure to increase future cure rates. This model is much like the one used in high-income countries, where enrolment in a clinical trial is deemed standard care, but diff ers in that each centre-or region, if conditions are similar across the region-must undertake its own implementation research to identify gaps and areas for improvement. For example, the Central American Paediatric Haematology-Oncology Association, which comprises eight centres in seven countries, uses uniform protocols National government % National private non-profit % Industry % International % Other % None % Series that have been adapted to the local setting, and carefully monitors outcomes. These outcomes include death from treatment toxicity and abandonment of treatment, which are the two most common causes of treatment failure for children with cancer. 55 Twinning programmes for individual centres, and regional networks of similar
Proposal
Comments Diffi culty When achievable
Health systems and health policy
Diff erent outcomes between children from affl uent and deprived backgrounds
Research into the inequalities in outcomes of childhood cancers and the development of new policies.
.. High complexity
Medium term
Insuffi cient aff ordable cancer care for most children in developing countries
New health-sector reforms that target the health of poor people, including improvements in tax to fi nance systems, reduction in cost of services to poor people and social insurance models, and policies that deliver services with equity and that have built in monitoring and evaluation targets. Develop a national childhood cancer plan with designated hospitals certifi ed to provide care, rapid referral systems, and access to care for the entire population.
Although many emerging economies are attempting to reform their systems, most are inequitable and have major structural defi cits. The delivery of aff ordable care for children with cancer is associated with overall health-care reform. However, model initiatives can and should be developed to act as leaders both within and outside of the country.
High complexity Medium term
Insuffi cient civil society and advocacy to deliver current Millennium Development Goals relevant to child health Promote the growth of civil society in low-income countries to support the fi nancial situation of existing childhood cancer providers, with the International Confederation of Childhood Cancer Patient Organisation to support and develop national organisations.
The separation between infectious and non-communicable diseases is artifi cial, and is counterproductive in public policy terms. The international childhood-cancer advocacy movement needs to deliver its agenda by supporting broader child health goals and helping the childhood cancer community to advocate for the Millenium Development Goals. High-quality epidemiological data for health-care system planning for childhood cancers is crucial and the knowledge already exists. However, many lower-middle-income and low-income countries will need substantial technical and fi nancial assistance from high-income sources to address this issue, including initiatives from major research funders.
Easy to deliver Deliverable now
Poor remuneration of health-care professionals working in the public sector Specialisation of multidisciplinary health-care professionals needed to treat cancer in children and adolescents should be recognised and appropriately remunerated alongside career development.
Health-care workers in countries of low and middle income are poorly remunerated such that they often have to rely on additional (non-specialist) activities or move overseas.

Research and development
Insuffi cient sustainable funding mechanisms in all countries
Government and philanthropic funders to create long-term core infrastructure research and development funds. Increased strategic planning between national and international funders of research and development. Dedicated low-income and middle-income research and development funding streams.
Although funding levels have been good in high-income countries, the increasing trend to short-term funding works against long-term programmes. Conversely, in low-income and middle-income countries, levels of research and development funding are too low Policy makers should provide government-based economic modelseg, the US National Cancer Institute-funded Pediatric Preclinical Testing Program-to support key steps for the development of childhood medicines against ultra-rare targets and other novel targets. In countries where federal engagement is suboptimum, strategies that give advocacy groups public-relations materials to lobby for specifi c solutions can be very eff ective. At the national and international level-eg, FP7 European Network for Cancer Research in Children and Adolescents-policy is urgently needed to create sustainable funding streams to support the international networks. Series centres, provide the forum for international mentoring, development of regional expertise, and generation of generalisable knowledge that will help others who treat children with cancer. 21 The support of twinning programmes and regional networks-and holding them accountable for measurable results-could transform cancer care, provide the platform to integrate new drugs and targeted treatments on a global scale in the intermediate term, and lead to excellent cure rates for all children everywhere in the long term.
Easy to deliver
Conclusions
The experiences and needs of children with cancer and their families in all settings, whether a high-income or a developing country, need to be better understood. 56 Policy development needs evidence and experience. The table shows the policies proposed here and in the other three papers [14] [15] [16] in this Series to focus our eff orts to address the global needs of children with cancer. We need a broad and transdisciplinary approach to these issues that brings in expertise from outside the Pan-community models of collaboration (parents, academia, industry, and regulators) should commit to medium-term and longterm partnerships to deliver the next generation of innovations.
Harmonisation between procedures and processes between EU groups (eg, ENCCA) and North America (COG) to encourage collaboration and speed up the development and delivery of advancements in treatment. Incorporation of regional networks of centres in low-income and middle-income countries to provide access to up-to-date treatments and to greatly increase the number of patients able to participate in clinical research and provide samples for translational research.
The pharmaceutical industry should positively engage with the paediatric research and development networks to create a new collaborative model that brings funding, and new molecules and biomarkers, into the existing clinical trial networks.
Easy to deliver Deliverable now
Threats to availability of data on cancer burden
Legislatively mandated programme to create or sustain population-based cancer registries, ideally with national coverage for childhood populations. To avoid bias, should not need informed consent or one-way encryption of the identifying data for population-based cancer registration. Relieve constraints on publication of grouped cancer data to encourage research for the benefi t of future patients. Transnational support to create an international childhood cancer survivor registries research programme that builds on existing structures is urgently needed.
Ensure data protection requirements do not jeopardise the ability for clinical trial groups or national health services to share data for pooled analyses that contribute to improved patient outcomes.
Medium complexity Medium term
Regulatory frameworks All national and international legislative mechanisms (eg, EU 27) should have formal mechanisms in place to include childhood cancer research within any impact assessment. Additionally, policy makers and regulators urgently need to positively engage with the clinical tri als and population-based research communities as current legislation is reviewed and updated. Regulators should consider several additional improvements to paediatric investigation plans: consideration of the mechanism of action of drug rather than the adult condition; reconsideration of the waiving process; improved consideration of what is done and planned in a given paediatric cancer through drug development strategies established for each disease; development of paediatric investigation plans that address several targets from diff erent companies for the same disease; and developing mechanisms within the paediatric regulatory framework that prioritise unmet clinical needs, led by the paediatric oncology community in partnership with parents and industry.
.. Series traditional childhood cancer community, and also leverages the solidarity that exists between all the communities involved in the care, research, and education agendas in childhood cancer. The delivery of improved global outcomes for children with cancer will need creative policy solutions to many issues, from fundamental biology to the delivery of new educational systems for sick children. Agreement, solidarity, and mutual help will be the most important means to fulfi l these policy recommendations. In 2023, we should be able to look back and see real improvements in all the issues raised in this Series; although many goals are ambitious, none are out of reach.
Easy to deliver Medium term
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